Dianthus Therapeutics, Inc. (DNTH) Dianthus Therapeutics, Inc., a clinical-stage biotechnology company, develops complement therapeutics for patients with severe autoimmune and inflammatory diseases. Soleno Therapeutics, Inc. (SLNO) Soleno Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of novel therapeutics for the treatment of rare diseases. Super Micro Computer, Inc. (SMCI) Super Micro Computer, Inc., together […]
Read MoreDyne Therapeutics, Inc. is a biotechnology company focused on developing life-transforming therapies for patients with serious muscle diseases. The company utilizes its proprietary FORCE™ platform to deliver targeted therapies that address the underlying genetic causes of muscle disorders. Dyne Therapeutics’ pipeline includes treatments for diseases such as Duchenne muscular dystrophy (DMD), myotonic dystrophy type 1 […]
Read MoreTaysha Gene Therapies, Inc. (TSHA) is a biotechnology company dedicated to developing and commercializing gene therapies for the treatment of severe monogenic diseases of the central nervous system (CNS). The company focuses on using adeno-associated viruses (AAVs) as vectors to deliver therapeutic genes to target cells, aiming to address the root causes of these diseases. […]
Read MoreNeurogene Inc. (NGNE) is a biotechnology company dedicated to developing life-changing genetic therapies for patients suffering from rare neurological diseases. Their primary focus is on creating innovative treatments that address the root causes of these disorders at the genetic level. Neurogene’s key product candidates include gene therapy programs aimed at conditions such as Batten disease […]
Read MoreStoke Therapeutics, Inc. (STOK) is a biotechnology company focused on developing innovative treatments for genetic diseases. Their primary aim is to address severe genetic disorders by upregulating protein expression using their proprietary TANGO (Targeted Augmentation of Nuclear Gene Output) platform. This platform allows Stoke to precisely increase the production of proteins that are deficient due […]
Read MoreHeron Therapeutics is a biotechnology company that focuses on developing and commercializing treatments to address unmet medical needs, particularly in the areas of pain management and oncology. The company leverages its proprietary Biochronomer drug delivery technology to create innovative therapies that can improve patient outcomes and quality of life.One of Heron Therapeutics’ key products is […]
Read MoreJanux Therapeutics Inc. JANX is a biotechnology company specializing in the development of novel cancer immunotherapies designed to enhance the body’s ability to harness the immune system to combat cancer. The company focuses on creating therapies that are not only effective but also have reduced side effects, improving patient outcomes in the fight against cancer. […]
Read MoreADC Therapeutics focuses on advancing its proprietary antibody drug conjugate (ADC) technology platform to transform the treatment paradigm for patients with hematologic malignancies and solid tumors. Its flagship product is ZYNLONTA, a CD19-directed ADC, received accelerated approval from the U.S. Food and Drug Administration and conditional approval from the European Commission for the treatment of […]
Read MoreJasper Therapeutics, Inc., a clinical-stage biotechnology company, develops therapeutic agents for hematopoietic stem cell transplantation and gene therapies. It focuses on the development and commercialization of therapeutic agents for diseases, such as chronic spontaneous urticaria, lower to intermediate risk myelodysplastic syndrome, and novel conditioning regimens for stem cell transplantation and ex-vivo gene therapy, a technique […]
Read MoreQudian Inc. (QD) Qudian Inc. operates as a consumer-oriented technology company in the People’s Republic of China. It engages in the operation of online platforms to provide small consumer credit products, as well as provides technology development and services and research and development services. Afya Limited (AFYA) Afya Limited, through its subsidiaries, operates as a […]
Read MoreImmunityBio, Inc. (IBRX) ImmunityBio, Inc., a clinical-stage biotechnology company, engages in developing therapies and vaccines that complement, harness, and amplify the immune system to defeat cancers and infectious diseases in the United States and Europe. Super Micro Computer, Inc. (SMCI) Super Micro Computer, Inc., together with its subsidiaries, develops and manufactures high performance server and storage solutions […]
Read MoreSavara is a clinical-stage biopharmaceutical company focused on rare respiratory diseases. Their lead product candidate, molgramostim, is an inhaled granulocyte-macrophage colony-stimulating factor (GM-CSF) in Phase 3 development for autoimmune pulmonary alveolar proteinosis (aPAP). Autoimmune PAP is a disease that belongs to a family of distinct, rare lung diseases collectively referred to as PAP. Autoimmune PAP […]
Read MoreShattuck Labs, Inc., a clinical-stage biotechnology company, develops therapeutics for the treatment of cancer and autoimmune disease in the United States. The company’s lead product candidate is SL-172154, which is in Phase 1 clinical trial for the treatment of ovarian, fallopian tube, and peritoneal cancers. The company was incorporated in 2016 and is headquartered in […]
Read MoreImmunoGen, Inc. (IMGN) ImmunoGen, Inc., a commercial-stage biotechnology company, focuses on developing and commercializing the antibody-drug conjugates (ADCs) for cancer patients. Abercrombie & Fitch Co. (ANF) Abercrombie & Fitch Co., through its subsidiaries, operates as a specialty retailer in the United States, Europe, the Middle East, Asia, the Asia-Pacific, Canada, and internationally. XPO, Inc. (XPO) […]
Read MoreOlema Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of therapies for women’s cancers. Its lead product candidate is OP-1250, an estrogen receptor (ER) antagonist and a selective ER degrader, which is in Phase 1/2 clinical trial for the treatment of recurrent, locally advanced, or metastatic estrogen receptor-positive, human epidermal […]
Read More